A gastrointestinal anti-infectious biotherapeutic agent: The heat-treated Lactobacillus LB

Therapeutic Advances in Gastroenterology

Volumn 9, Issue 1, 2016, Pages 57-75

  Lievin Moal, Vanessa ^a  

^a UNIVERSITÉ PARIS SUD   (France)

Author keywords

antibacterial; biotherapeutic; diarrhoea; enterovirulent Escherichia coli; gastroenteritis; Lactobacillus; Lactobacillus acidophilus LB; pharmabiotic; probiotic; Salmonella

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEFALOTIN; ERYTHROMYCIN; GENTAMICIN; ORAL REHYDRATION SOLUTION; PLACEBO; PROBIOTIC AGENT; TETRACYCLINE; VIRULENCE FACTOR;

ABSENCE OF SIDE EFFECTS; ACUTE DIARRHEA; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC ASSOCIATED DIARRHEA; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ADHERENCE; CAMPYLOBACTER ENTERITIS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FREEZE DRYING; GASTRITIS; HEAT TREATMENT; HUMAN; INFECTIOUS ACUTE WATERY DIARRHEA; INTESTINE FLORA; LACTOBACILLUS; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LACTOBACILLUS DELBRUECKII; LACTOBACILLUS FERMENTUM; LACTOBACILLUS JOHNSONII; LACTOBACILLUS REUTERI; LACTOBACILLUS RHAMNOSUS; NONHUMAN; ORAL REHYDRATION THERAPY; PRIORITY JOURNAL; REVIEW; SACCHAROMYCES BOULARDII;

EID: 84951810892     PISSN: 1756283X     EISSN: 17562848     Source Type: Journal    
DOI: 10.1177/1756283X15602831     Document Type: Review

References (81)

1. Allen S. Martinez E. Gregorio G. Dans L. (2010) Probiotics for treating acute infectious diarrhoea. Cochrane Database Syst Rev: CD003048.
2. Andresen V. Layer P. Menge D. Keller J. (2012) Efficacy of freeze-dried Lactobacilli in functional diarrhoea: a pilot study. Dtsch Med Wochenschr 137: 1792–1796.
3. Boulloche J. Mouterde O. Mallet E. (1994) Management of acute diarrhoea in infants and young children: controlled study of the anti-diarrhoeal efficacy of killed L. acidophilus (LB Strain) versus a placebo and a reference drug (loperamide). Ann Pediatr 41: 457–463.
4. Briand V. Buffet P. Genty S. Lacombe K. Godineau N. Salomon J. et al. (2006) Absence of efficacy of nonviable Lactobacillus acidophilus for the prevention of traveler's diarrhea: a randomized, double-blind, controlled study. Clin Infect Dis 43: 1170–1175.
5. Chauviere G. Coconnier M. Kerneis S. Darfeuille-Michaud A. Joly B. Servin A. (1992 a) Competitive exclusion of diarrheagenic Escherichia coli (ETEC) from human enterocyte-like Caco-2 cells by heat-killed Lactobacillus. FEMS Microbiol Lett 70: 213–217.
6. Chauviere G. Coconnier M. Kerneis S. Fourniat J. Servin A. (1992 b) Adhesion of human Lactobacillus acidophilus strain LB to human enterocyte-like Caco-2 cells. J Gen Microbiol 138: 1689–1696.
7. Chauviere G. Gastebois B. Liévin-Le Moal V. Polter M. Servin A. (2005) Lactobacillus fermentum strain and uses thereof. European Patent EP 1608737 A1.
8. Coconnier M. Bernet M. Chauviere G. Servin A. (1993 a) Adhering heat-killed human Lactobacillus acidophilus, strain LB, inhibits the process of pathogenicity of diarrhoeagenic bacteria in cultured human intestinal cells. J Diarrhoeal Dis Res 11: 235–242.
9. Coconnier M. Bernet M. Kerneis S. Chauviere G. Fourniat J. Servin A. (1993 b) Inhibition of adhesion of enteroinvasive pathogens to human intestinal Caco-2 cells by Lactobacillus acidophilus strain LB decreases bacterial invasion. FEMS Microbiol Lett 110: 299–305.
10. Coconnier M. Liévin V. Bernet-Camard M. Hudault S. Servin A. (1997) Antibacterial effect of the adhering human Lactobacillus acidophilus strain LB. Antimicrob Agents Chemother 41: 1046–1052.
11. Coconnier M. Liévin V. Hemery E. Servin A. (1998) Antagonistic activity against Helicobacter infection in vitro and in vivo by the human Lactobacillus acidophilus strain LB. Appl Environ Microbiol 64: 4573–4580.
12. Coconnier M. Liévin V. Lorrot M. Servin A. (2000) Antagonistic activity of Lactobacillus acidophilus LB against intracellular Salmonella enterica serovar typhimurium infecting human enterocyte-like Caco-2/TC-7 cells. Appl Environ Microbiol 66: 1152–1157.
13. Coconnier-Polter M. Liévin-Le Moal V. Servin A. (2005) A Lactobacillus acidophilus strain of human gastrointestinal microbiota origin elicits killing of enterovirulent Salmonella enterica Serovar typhimurium by triggering lethal bacterial membrane damage. Appl Environ Microbiol 71: 6115–6120.
14. Cover T. Blaser M. (2009) Helicobacter pylori in health and disease. Gastroenterology 136: 1863–1873.
15. Croxen M. Law R. Scholz R. Keeney K. Wlodarska M. Finlay B. (2013) Recent advances in understanding enteric pathogenic Escherichia coli. Clin Microbiol Rev 26: 822–880.
16. Del Piano M. Morelli L. Strozzi G. Allesina S. Barba M. Deidda F. et al. (2006) Probiotics: from research to consumer. Dig Liver Dis 38: S248–S255.
17. Fabrega A. Vila J. (2013) Salmonella enterica serovar typhimurium skills to succeed in the host: virulence and regulation. Clin Microbiol Rev 26: 308–341.
18. FAO/WHO (2001) Report of a joint FAO / WHO expert consultation on evaluation of health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. Cordoba, Argentina, 1–4 October 2001. Rome: World Health Organization and Food and Agricultural Organization of the United Nations.
19. FAO/WHO (2002) Report of a joint FAO / WHO working group on drafting guidelines for the evaluation of probiotics in food. Rome: World Health Organization and Food and Agricultural Organization of the United Nations.
20. Floch M. Madsen K. Jenkins D. Guandalini S. Katz J. Onderdonk A. et al. (2006) Recommendations for probiotic use. J Clin Gastroenterol 40: 275–278.
21. Foster L. Tompkins T. Dahl W. (2011) A comprehensive post-market review of studies on a probiotic product containing Lactobacillus helveticus R 0052 and Lactobacillus rhamnosus R0011. Benef Microbes 2: 319–334.
22. Fourniat J. Colomban C. Linxe C. Karam D. (1992) Heat-killed Lactobacillus acidophilus inhibits adhesion of Escherichia coli B 41 to HeLa cells. Ann Rech Vet 23: 361–370.
23. Fourniat J. Djaballi Z. Maccario J. Bourlioux P. German A. (1986) Effect of the administration of killed Lactobacillus acidophilus on the survival of suckling mice infected with a strain of enterotoxigenic Escherichia coli. Ann Rech Vet 17: 401–407.
24. Gareau M. Sherman P. Walker W. (2010) Probiotics and the gut microbiota in intestinal health and disease. Nat Rev Gastroenterol Hepatol 7: 503–514.
25. Guarino A. Albano F. Ashkenazi S. Gendrel D. Hoekstra J. Shamir R. et al. (2008) European Society for Paediatric Gastroenterology, Hepatology, and Nutrition / European Society for Paediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe. J Pediatr Gastroenterol Nutr 46(Suppl. 2): S81–S122.
26. Halpern G. Prindiville T. Blankenburg M. Hsia T. Gershwin M. (1996) Treatment of irritable bowel syndrome with Lactéol Fort: a randomized, double-blind, cross-over trial. Am J Gastroenterol 91: 1579–1585.
27. Hagbom M. Sharma S. Lundgren O. Svensson L. (2012) Towards a human rotavirus disease model. Curr Opin Virol 2: 408–418.
28. Hempel S. Newberry S. Maher A. Wang Z. Miles J. Shanman R. et al. (2012) Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA 307: 1959–1969.
29. Hempel S. Newberry S. Ruelaz A. Wang Z. Miles J. Suttorp M. et al. (2011) Safety of probiotics used to reduce risk and prevent or treat disease. Report / Technology Assessment No. 200. AHRQ Publication No. 11-E007. Rockville, MD: Agency for Healthcare Research and Quality.
30. Hickson M. (2011) Probiotics in the prevention of antibiotic-associated diarrhoea and Clostridium difficile infection. Therap Adv Gastroenterol 4: 185–197.
31. Hill C. Guarner F. Reid G. Gibson G. Merenstein D. Pot B. et al. (2014) Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 11: 506–514.
32. Hoffman F. (2008) Development of probiotics as biologic drugs. Clin Infect Dis 46(Suppl. 2): S125–S127.
33. Isidean S. Riddle M. Savarino S. Porter C. (2011) A systematic review of ETEC epidemiology focusing on colonization factor and toxin expression. Vaccine 29: 6167–6178.
34. Johnston B. Goldenberg J. Vandvik P. Sun X. Guyatt G. (2011) Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev: CD004827.
35. Johnston B. Ma S. Goldenberg J. Thorlund K. Vandvik P. Loeb M. Guyatt G. (2012) Probiotics for the prevention of Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Ann Intern Med 157: 878–888.
36. Kleerebezem M. Hols P. Bernard E. Rolain T. Zhou M. Siezen R. Bron P. (2010) The extracellular biology of the lactobacilli. FEMS Microbiol Rev 34: 199–230.
37. Lebeer S. Vanderleyden J. de Keersmaecker S. (2008) Genes and molecules of lactobacilli supporting probiotic action. Microbiol Mol Biol Rev 72: 728–764.
38. Lebeer S. Vanderleyden J. de Keersmaecker S. (2010) Host interactions of probiotic bacterial surface molecules: comparison with commensals and pathogens. Nat Rev Microbiol 8: 171–184.
39. Lewis K. (2007) Persister cells, dormancy and infectious disease. Nat Rev Microbiol 5: 48–56.
40. Li Xie B. (1995) Controlled clinical trial in infants and children comparing Lactéol Fort sachets with two antidiarrhoeal reference drugs Ann Pediatr 42: 396–401.
41. Liévin-Le Moal V. Amsellem R. Servin A. (2011) Impairment of swimming motility by antidiarrheic Lactobacillus acidophilus strain LB retards internalization of Salmonella enterica serovar typhimurium within human enterocyte-like cells. Antimicrob Agents Chemother 55: 4810–4820.
42. Liévin-Le Moal V. Amsellem R. Servin A. Coconnier M. (2002) Lactobacillus acidophilus (strain LB) from the resident adult human gastrointestinal microflora exerts activity against brush border damage promoted by a diarrhoeagenic Escherichia coli in human enterocyte-like cells. Gut 50: 803–811.
43. Liévin-Le Moal V. Sarrazin-Davila L. Servin A. (2007) An experimental study and a randomized, double-blind, placebo-controlled clinical trial to evaluate the antisecretory activity of Lactobacillus acidophilus strain LB against nonrotavirus diarrhea. Pediatrics 120: e795–e803.
44. Liévin-Le Moal V. Servin A. (2014) Anti-infective activities of Lactobacillus strains in the human intestinal microbiota: from probiotics to gastrointestinal anti-infectious biotherapeutic agents. Clin Microbiol Rev 27: 167–199.
45. McFarland L. (2010) Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol 16: 2202–2222
46. Menees S. Saad R. Chey W. (2012) Agents that act luminally to treat diarrhoea and constipation. Nat Rev Gastroenterol Hepatol 9: 661–674.
47. Metchnikoff E. (1907) Lactic acid as inhibiting intestinal putrefaction. In: The Prolongation of Life: Optimistic Studies. London: Heinemann, pp. 161–183.
48. Mikelsaar M. Zilmer M. (2009) Lactobacillus fermentum ME-3 – an antimicrobial and antioxidative probiotic. Microb Ecol Health Dis 21: 1–27.
49. Montalto M. Maggiano N. Ricci R. Curigliano V. Santoro L. Di Nicuolo F. et al. (2004) Lactobacillus acidophilus protects tight junctions from aspirin damage in HT-29 cells. Digestion 69: 225–228.
50. Moyen E. Bonneville F. Fauchere J. (1986) Modification of intestinal colonization and translocation of Campylobacter jejuni by erythromycin and an extract of Lactobacillus acidophilus in axenic mice. Ann Inst Pasteur Microbiol 137A: 199–207.
51. Muller J. Stanton C. Sybesma W. Fitzgerald G. Ross R. (2010) Reconstitution conditions for dried probiotic powders represent a critical step in determining cell viability. J Appl Microbiol 108: 1369–1379.
52. Piescik-Lech M. Shamir R. Guarino A. Szajewska H. (2013) Review article: the management of acute gastroenteritis in children. Aliment Pharmacol Ther 37: 289–303.
53. Ritchie M. Romanuk T. (2012) A meta-analysis of probiotic efficacy for gastrointestinal diseases. PloS ONE 7: e34938.
54. Salazar-Lindo E. Figueroa-Quintanilla D. Caciano M. Reto-Valiente V. Chauviere G. Colin P. (2007) Effectiveness and safety of Lactobacillus LB in the treatment of mild acute diarrhea in children. J Pediatr Gastroenterol Nutr 44: 571–576.
55. Sanders M. Hamilton J. Reid G. Gibson G. (2007) A nonviable preparation of Lactobacillus acidophilus is not a probiotic. Clin Infect Dis 44: 886.
56. Sanders M. Klaenhammer T. (2001) Invited review: the scientific basis of Lactobacillus acidophilus NCFM functionality as a probiotic. J Dairy Sci 84: 319–331.
57. Sanders M. Klaenhammer T. Ouwehand A. Pot B. Johansen E. Heimbach J. et al. (2014) Effects of genetic, processing, or product formulation changes on efficacy and safety of probiotics. Ann N Y Acad Sci 1309: 1–18.
58. Segers M. Lebeer S. (2014) Towards a better understanding of Lactobacillus rhamnosus GG - host interactions. Microb. Cell Factories 13: 1–16.
59. Servin A. (2014) Pathogenesis of human diffusely adhering Escherichia coli expressing Afa / Dr adhesins (Afa/Dr DAEC): current insights and future challenges. Clin Microbiol Rev 27: 823–869.
60. Servin A. Coconnier M.H. Liévin V. Boisseau R. Houlier P. Chauvière G. (1999) Composition anti-bactérienne. European Patent EP 1000625 A1.
61. Servin A. Chauviere G. Polter M. Liévin-Le Moal V. Gastebois B. (2006) Lactobacillus fermentum strain and uses there of. US Patent 0,134,220.
62. Shanahan F. Stanton C. Ross R. Hill C. (2009) Pharmabiotics: bioactives from mining host-microbe-dietary interactions. Functionnal Food Rev. 1: 20–25.
63. Simakachorn N. Pichaipat V. Rithipornpaisarn P. Kongkaew C. Tongpradit P. Varavithya W. (2000) Clinical evaluation of the addition of lyophilized, heat-killed Lactobacillus acidophilus LB to oral rehydration therapy in the treatment of acute diarrhea in children. J Pediatr Gastroenterol Nutr 30: 68–72.
64. Sutton A. (2008) Product development of probiotics as biological drugs. Clin Infect Dis 46(Suppl. 2): S128–S132.
65. Szajewska H. Guarino A. Hojsak I. Indrio F. Kolacek S. Shamir R. et al. (2014 a) Use of probiotics for management of acute gastroenteritis: a position paper by the ESPGHAN Working Group for Probiotics and Prebiotics. J Pediatr Gastroenterol Nutr 58: 531–539.
66. Szajewska H. Gyrczuk E. Horvath A. (2013 a) Lactobacillus reuteri DSM 17938 for the management of infantile colic in breastfed infants: a randomized, double-blind, placebo-controlled trial. J Pediatr 162: 257–262.
67. Szajewska H. Ruszczynski M. Kolacek S. (2014 b) Meta-analysis shows limited evidence for using Lactobacillus acidophilus LB to treat acute gastroenteritis in children. Acta Paediatr 103: 249–255.
68. Szajewska H. Skorka A. (2009) Saccharomyces boulardii for treating acute gastroenteritis in children: updated meta-analysis of randomized controlled trials. Aliment Pharmacol Ther 30: 960–961.
69. Szajewska H. Skorka A. Dylag M. (2007 a) Meta-analysis: Saccharomyces boulardii for treating acute diarrhoea in children. Aliment Pharmacol Ther 25: 257–264.
70. Szajewska H. Skorka A. Ruszczynski M. Gieruszczak-Bialek D. (2007 b) Meta-analysis: Lactobacillus GG for treating acute diarrhoea in children. Aliment Pharmacol Ther 25: 871–881.
71. Szajewska H. Skorka A. Ruszczynski M. Gieruszczak-Bialek D. (2013 b) Meta-analysis: Lactobacillus GG for treating acute gastroenteritis in children – updated analysis of randomised controlled trials. Aliment Pharmacol Ther 38: 467–476.
72. Tarrerias A. Costil V. Vicari F. Letard J. Adenis-Lamarre P. Aisene A. et al. (2011) The effect of inactivated Lactobacillus LB fermented culture medium on symptom severity: observational investigation in 297 patients with diarrhea-predominant irritable bowel syndrome. Dig Dis 29: 588–591.
73. Thiagarajah J.R. Mark Donowitz M. Verkman A.L. (2015) Secretory diarrhoea: mechanisms and emerging therapies. Nat Rev Gastroenterol Hepatol 12: 446–457.
74. Turner J. (2009) Intestinal mucosal barrier function in health and disease. Nat Rev Immunol 9: 799–809.
75. van Baarlen P. Wells J. Kleerebezem M. (2013) Regulation of intestinal homeostasis and immunity with probiotic lactobacilli. Trends Immunol 34: 208–215.
76. Vandenplas Y. Huys G. Daube G. (2015) Probiotics: an update. J Pediatr 91: 6–21.
77. Verna E. Lucak S. (2010) Use of probiotics in gastrointestinal disorders: what to recommend? Therap Adv Gastroenterol 3: 307–319.
78. WGO (2012) World Gastroenterology Organisation global guideline: probiotics and prebiotics. J Clin Gastroenterol 46: 468–481.
79. Xiao S. Zhang D. Lu H. Jiang S. Liu H. Wang G. et al. (2003) Multicenter, randomized, controlled trial of heat-killed Lactobacillus acidophilus LB in patients with chronic diarrhea. Adv Ther 20: 253–260.
80. Yan F. Polk D. (2012) GG: An updated strategy to use microbial products to promote health. Funct Food Rev 4: 77–84.
81. Yap Soo Kor J. Gwee Kok A. Chen Z. Choo T. Wong Mee L. (2010) Lactéol Fort reduces antibiotic-associated diarrhea. Singapore Families Physician 36: 46–49.